Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Argent Biopharma ( (AU:RGT) ) has shared an update.
Argent BioPharma Ltd. announced that Mr. Layton Mills has resigned as a Non-Executive Director, with the resignation taking effect upon finding a suitable replacement. The company is in advanced discussions with potential candidates and will update shareholders once a decision is made. The board expressed gratitude for Mr. Mills’ contributions during his tenure. This change signifies a potential shift in board dynamics, potentially impacting company strategy and stakeholder interests.
More about Argent Biopharma
Argent BioPharma Limited is an innovative clinical-stage biopharmaceutical company focused on neuroimmunology, developing advanced nano-medicines for unmet medical needs in central nervous system disorders and immune-related conditions. Utilizing cutting-edge technologies like the Neuro-Immune Modulatory System, the company aims to reshape care for chronic, inflammatory, and neurodegenerative diseases with a pipeline that includes products such as CannEpil®, CogniCann®, and CimetrA®.
YTD Price Performance: 80.17%
Average Trading Volume: 136,308
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $4.78M
Learn more about RGT stock on TipRanks’ Stock Analysis page.
